Multicare Pharma and KalVista Pharmaceuticals Announce Agreement to Bring the First Oral On-demand Treatment for Hereditary Angioedema to Latin America
Multicare Pharma and KalVista Pharmaceuticals Announce Agreement to Bring the First Oral On-demand Treatment for Hereditary Angioedema to Latin America
New drug has the potential to become the first oral treatment indicated for the management of acute hereditary angioedema (HAE) attacks in Latin America.
Multicare Pharma provides rare disease expertise and broad capabilities to import and commercialize the new drug product in Latin America.
New drug has the potential to become the first oral treatment indicated for the management of acute hereditary angioedema (HAE) attacks in Latin America.
Multicare Pharma provides rare disease expertise and broad capabilities to import and commercialize the new drug product in Latin America.
– January, 2026 – Multicare Pharmaceuticals, LLC a leading Latin American company with extensive commercialization expertise in rare diseases, has entered into a partnership agreement in Brazil, Argentina, Columbia and Mexico with KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a global biopharmaceutical company focused on the development of novel treatments for rare diseases. Under the agreement, Multicare will be responsible for the regulatory registration, importation, and distribution of KalVista’s new treatment for HAE. The medicine is the first and only oral on-demand treatment for hereditary angioedema (HAE), currently marketed in the United States and European Union.
Financial terms of the agreement are not disclosed.
The new product is a novel plasma kallikrein inhibitor approved in the United States, European Union, United Kingdom, Switzerland, Singapore, Australia and Japan for the treatment of acute attacks of hereditary angioedema (HAE) in people 12 years of age and older. The product is the first and only oral on-demand treatment for HAE, offering efficacious and safe treatment of attacks without the burden of injections. With ongoing studies exploring its use in children aged two to 11 and multiple regulatory applications under review in key global markets, the medicine has the potential to become the foundational therapy for HAE management worldwide.
About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration.
About Multicare Pharmaceuticals
With more than 40 years of experience in Latin America, Multicare is the leading company in the licensing, registration, promotion, import, and distribution of innovative treatments. Focused on rare and complex diseases, the company ensures timely access to essential therapies and, in partnership with global companies such as KalVista, contributes to expanding healthcare across the region. For more information about Multicare Pharma, please visit http://www.multicarepharma.com.
About KalVista Pharmaceuticals, Inc.
KalVista is a global pharmaceutical company dedicated to delivering life-changing therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.
Multicare Contacts
Contact: Gabriela Bonomi – Manager, Advocacy and Corporate Communications
Email: gabriela.bonomi@multicarepharma.com
Phone: +55 (11) 93927-1793
Media Inquiries
Contact: Tino Comunicação
Email: regiane@tinocomunicacao.com.br | danilo@tinocomunicacao.com.br
Phone: +55 (11) 99786-7200